Tatva Chintan Soars: Net Sales Up 65%, Net Profit Jumps 1472% in Dec 2025 Quarter

• Tatva Chintan Pharma Chem reported a significant increase in Standalone Net Sales, reaching Rs 138.59 crore in December 2025, a 64.99% rise year-over-year.
• Quarterly Net Profit for December 2025 surged by an impressive 1472.02% to Rs 15.98 crore, compared to Rs 1.17 crore in December 2024.
• EBITDA also saw substantial growth, increasing by 399.3% to Rs 28.36 crore in December 2025.
• The company's Earnings Per Share (EPS) rose to Rs 6.84 in December 2025 from Rs 0.50 in December 2024.
• Tatva Chintan shares have delivered strong returns, with 34.51% over the last 6 months and 64.40% over the last 12 months as of January 20, 2026.

Why It Matters: Tatva Chintan Pharma Chem demonstrated exceptional financial performance in Q3 FY25 with massive profit and sales growth.